Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
Respiratory medicine and research(2023)
Abstract
Our study suggests that EI dosing of ICIs did not affect toxicity and overall survival in lung cancer patients.
MoreTranslated text
Key words
COVID 19-pandemic,Immune checkpoint inhibitors,Immune-related toxicity,Lung cancer
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined